Rating Change
Rodman & Renshaw analysts initiated coverage on Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) with a Buy rating on July 21, 2026.
new coverageNASDAQ:ELDN
Rodman & Renshaw Initiates Coverage on Eledon Pharmaceuticals, Inc. (ELDN) with Buy
Rating Change Rodman & Renshaw analysts initiated coverage on Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) with a Buy rating on July 21, 2026. Market Context Eledon Pharmaceuticals,…
Market Context
Eledon Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $3.94 with a market capitalization of $102.4M.
Analyst coverage from Rodman & Renshaw provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Eledon Pharmaceuticals, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Eledon Pharmaceuticals, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 21, 2026 | Rodman & Renshaw | Buy | N/A |
| Nov 18, 2025 | Guggenheim | Buy | N/A |
| Sep 02, 2025 | HC Wainwright & Co. | Buy | N/A |
| Jul 25, 2025 | Craig-Hallum | Buy | N/A |
| Nov 20, 2024 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ELDN Stock Page
Frequently Asked Questions
What does a Buy rating mean for ELDN?
A Buy rating from Rodman & Renshaw reflects the analyst's outlook on Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ELDN forecast page.